MediPharm Labs (LABS) Competitors C$0.06 0.00 (0.00%) As of 07/9/2025 02:52 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock LABS vs. TGOD, NINE, SUGR, WMD, MDP, VM, WLLW, HEXO, VIR, and ZOMShould you be buying MediPharm Labs stock or one of its competitors? The main competitors of MediPharm Labs include Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), SugarBud Craft Growers (SUGR), WeedMD (WMD), Medexus Pharmaceuticals (MDP), Voyageur Pharmaceuticals (VM), Willow Biosciences (WLLW), HEXO (HEXO), Viridium Pacific Group (VIR), and Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM). These companies are all part of the "drug manufacturers - specialty & generic" industry. MediPharm Labs vs. Its Competitors Green Organic Dutchman Delta 9 Cannabis SugarBud Craft Growers WeedMD Medexus Pharmaceuticals Voyageur Pharmaceuticals Willow Biosciences HEXO Viridium Pacific Group Zomedica Pharmaceuticals Corp. (ZOM.V) Green Organic Dutchman (TSE:TGOD) and MediPharm Labs (TSE:LABS) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk. Is TGOD or LABS more profitable? Green Organic Dutchman has a net margin of 0.00% compared to MediPharm Labs' net margin of -30.56%. Green Organic Dutchman's return on equity of 0.00% beat MediPharm Labs' return on equity.Company Net Margins Return on Equity Return on Assets Green Organic DutchmanN/A N/A N/A MediPharm Labs -30.56%-24.41%-7.17% Does the media favor TGOD or LABS? In the previous week, Green Organic Dutchman's average media sentiment score of 0.00 equaled MediPharm Labs'average media sentiment score. Company Overall Sentiment Green Organic Dutchman Neutral MediPharm Labs Neutral Do institutionals & insiders believe in TGOD or LABS? 0.7% of MediPharm Labs shares are owned by institutional investors. 4.5% of MediPharm Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher earnings and valuation, TGOD or LABS? MediPharm Labs has higher revenue and earnings than Green Organic Dutchman. MediPharm Labs is trading at a lower price-to-earnings ratio than Green Organic Dutchman, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGreen Organic DutchmanC$31.37M0.00-C$137.58M-C$0.26N/AMediPharm LabsC$39.42M0.68-C$12.05M-C$0.03-2.24 SummaryMediPharm Labs beats Green Organic Dutchman on 5 of the 9 factors compared between the two stocks. Get MediPharm Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for LABS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LABS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LABS vs. The Competition Export to ExcelMetricMediPharm LabsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$26.98MC$2.16BC$5.51BC$6.19BDividend YieldN/A2.92%5.25%6.72%P/E Ratio-2.244.1428.0252.25Price / Sales0.68555.42410.251,088.92Price / Cash1.3010.3537.0683.29Price / Book0.5911.678.144.69Net Income-C$12.05MC$21.15BC$3.16BC$301.20M7 Day PerformanceN/A0.96%3.13%0.59%1 Month PerformanceN/A6.75%3.47%3.61%1 Year PerformanceN/A3.72%34.20%26.93% MediPharm Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LABSMediPharm LabsN/AC$0.07flatN/A-7.1%C$26.98MC$39.42M-2.24130TGODGreen Organic DutchmanN/AN/AN/AN/AC$89.95MC$31.37M-0.6541Gap UpHigh Trading VolumeNINEDelta 9 CannabisN/AC$1.03+3.0%N/A+0.0%C$89.36MC$12.87M19.07940News CoverageGap UpSUGRSugarBud Craft GrowersN/AC$13.00-3.0%N/A+59.4%C$88.66MC$575.64M15.6644WMDWeedMDN/AC$0.28-1.8%N/A+0.0%C$67.82MC$27.53M-0.66628Gap UpMDPMedexus Pharmaceuticals1.8116 of 5 starsC$3.01flatC$5.49+82.3%+21.8%C$67.39MC$100.25M14.3998Negative NewsVMVoyageur PharmaceuticalsN/AC$0.29+5.5%N/A+420.0%C$43.94MN/A-27.12N/AWLLWWillow BiosciencesN/AC$0.27+8.0%N/A+125.0%C$39.11MC$2.94M-4.9419Gap UpHEXOHEXON/AN/AN/AN/AC$38.72MC$124.10M-0.26690VIRViridium Pacific GroupN/AC$0.38+5.6%N/A+0.0%C$37.52MC$1.09M-2.97580Gap UpZOMZomedica Pharmaceuticals Corp. (ZOM.V)N/AC$0.29-6.6%N/A+0.0%C$36.73MN/A-2.6150Gap Down Related Companies and Tools Related Companies Green Organic Dutchman Competitors Delta 9 Cannabis Competitors SugarBud Craft Growers Competitors WeedMD Competitors Medexus Pharmaceuticals Competitors Voyageur Pharmaceuticals Competitors Willow Biosciences Competitors HEXO Competitors Viridium Pacific Group Competitors Zomedica Pharmaceuticals Corp. (ZOM.V) Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:LABS) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredHow a Kansas farm boy gained 1,285% in two daysA former farm kid placed a simple trade… and cashed out a 1,285% gain two days later. It wasn’t crypto or a...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting—or plan to collect—Social Security, this could be a game-changer. A new initiative tie...InvestorPlace | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediPharm Labs Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediPharm Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.